Interview with Jacques Servier, Founder, Servier France
Do you feel the industry has changed more over the past ten years than over the entire 40 years before? It’s an optical illusion. People always have had the feelings…
Address: 22, Rue Garnier 92200 Neuilly sur Seine,France
Tel: +33 (0)1 55 72 60 00
Our entire activity is based on three key principles:
• Our chief principle, naturally, is to satisfy the needs of the physicians who prescribe our products and of the patients who benefit from them.
• Just as importantly, we want our research to contribute to the progress of medicine. Research to us is at least as vital as being an industry.
• Our third principle is all the more crucial as it is too often overlooked: it is that every person working for us should find fulfillment through and in what they do.
Figures
• Leading French independent pharmaceutical company
• Second French pharmaceutical company worldwide
• SERVIER is established in 140 countries
• 85% of SERVIER’s sales are achieved internationally
• Consolidated turnover for the 2007/2008 financial year: €3.7 billion
• More than 25% of SERVIER’s turnover is invested in Research and Development
• Worldwide workforce of over 20 000, including nearly 3 000 in Research and Development
• SERVIER contributes 29% of the trade surplus of France’s pharmaceutical industry
Osteoporosis
Diabetes
Cardiovascular
Venous Diseases
Do you feel the industry has changed more over the past ten years than over the entire 40 years before? It’s an optical illusion. People always have had the feelings…
How can mid-sized European pharmaceutical companies, which lack the scale of both Big Pharma and the major generics players, compete in a country like France? Norgine – a specialist player…
When Marc de Garidel joined AbiVax as CEO in 2023, the firm had very recently teetered on the brink of bankruptcy. Now, less than three short years later, he leads…
France finally has a full budget for 2026, ending months of stasis, and providing a degree of certainty to industry. However, especially for pharma, continual price cuts threaten the sustainability…
As global vaccine development grows more complex and capital more selective, Valneva is sharpening its identity and returning decisively to its roots. The company’s decision to close its Nantes site…
As metabolic liver disease rises rapidly up the global health agenda, Professor Cyrielle Caussy stands at the intersection of clinical care, translational research, and therapeutic innovation. A Professor of Nutrition…
Stéphane Legastelois has spent 35 years bridging science and business. After founding Indicia, he transitioned to healthcare investing, backing 30 early-stage companies, mainly in Lyon, and now heads up 33…
Denmark and France are intensifying their cooperation in life sciences at a time when resilience, innovation and industrial capacity have become strategic priorities for Europe. In this interview, Hanne Fugl…
Born from personal tragedy, Imagine for Margo has evolved into a pan-European force reshaping how childhood cancers are researched, funded, and brought to the policy agenda. Drawing on a parent’s…
Raymond Le Moign leads one of Europe’s largest university hospital centres at a moment when healthcare systems are being forced to rethink how they organise care, innovation, and accountability. Drawing…
A new chapter in vital organ care is unfolding as Vantive establishes its identity as an independent, purpose-driven leader in kidney care. With Trushar Patel stepping into an expanded leadership…
Kyowa Kirin’s new head for France and Benelux steps into the role at a time when rare diseases, regulatory expectations and scientific modalities are all shifting at speed. In this…
Biogen France is operating at a moment of profound change, where rapid advances in neurology, immunology and rare diseases intersect with shifting global dynamics on investments to innovation and new…
See our Cookie Privacy Policy Here
